Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab

Bevacizumab is now an emerging treatment option for severe hereditary hemorrhagic telangiectasia–related bleeding including epistaxis and gastrointestinal tract bleeding. The impact of long-term intravenous bevacizumab therapy on cardiac structure and function is unknown. We describe 3 patients rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Albitar, Hasan Ahmad, Almodallal, Yahya, Nishimura, Rick, Iyer, Vivek N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411168/
https://www.ncbi.nlm.nih.gov/pubmed/32793873
http://dx.doi.org/10.1016/j.mayocpiqo.2020.01.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411168/
https://www.ncbi.nlm.nih.gov/pubmed/32793873
http://dx.doi.org/10.1016/j.mayocpiqo.2020.01.002

Ejemplares similares